Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q1 FY27 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Jul 30, 2026
Slide 1: Exchange cover letter: Investor Presentation Q1 FY 26-27
July 30, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref
Slide 2: Investor Presentation Q1 FY27
Investor Presentation Q1 FY27
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q1 FY27 Highlights
Q1 FY27 | Highlights “We are pleased to begin the first quarter of FY27 on a positive note demonstrating the resilience of our business model, strong execution and accelerating traction in the non-GPL business. With recently launched products continuing to gain scale across geographies, we remain co
Slide 6: Q1 FY27 Performance
Q1 FY27 Performance Revenue EBITDA PAT EPS (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹) EBITDA Margin PAT Margin 6,891 36.4% 25.0% 13.23 36.6% 23.6% 13.04 6,729 34.4% 22.1% 22.3% 12.25 33.0% 1,627 1,601 6,404 30.1% 20.2% 2,452 1,503 10.60 2,373 2,341 9.91 6,018 1,301 5,880 1,215 1,93
Slide 7: P&L Highlights Q1 FY27
P&L Highlights | Q1 FY27 Particulars (In ₹ Million) Q1 FY27 Q4 FY26 QoQ Q1 FY26 YoY FY26 Revenue from Operations 6,404 6,891 -7.1% 6,018 6.4% 25,518 Gross Profit 3,854 4,182 -7.8% 3,315 16.3% 14,853 Gross Profit (%) 60.2% 60.7% -50 bps 55.1% +510 bps 58.2% Other Income 224 228 -1.8% 90 148.9% 604 Em
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 34% 32% 32% 30% 2.9 27% 2.7 2.5 2.2 2.2 FY23 FY24 FY25 FY26 Q1FY27 FY23 FY24 FY25 FY26 Q1FY27 • ROICE is tracking at ~32% – Capital employed was driven by a calibrated Capex strategy • FATR is 2.2 times – Asset turns have trended slig
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Mil l ion ) (In ₹ Mill i on ) (In ₹ Mill i on ) (In ₹) EBITDA Margin PAT Margin 33.6% 25,518 31.4% 31.1% 30.1% 30.0% 21.6% 22.1% 45.99 20.6% 20.3% 23,869 19.7% 22,832 8,577 5,645 21,612 39.63 21,232 38.43 38.11 35.63 4,857 7,172 4,709
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance: Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenu e In ₹ Milli o n ) (Revenu e In ₹ Milli o n ) 556 6,343 6,070 453 5,921 5,513 5,464 364 378 278 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1Y27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1Y27 • CDMO business saw a growth of 3.8% YoY in • Generic API revenues
Slide 12: Segmental Performance: GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ Mill i on ) (In ₹ Mill i on ) 35.4% 88.7% 30.0% 75.6% 74.6% 25.4% 2,439 70.0% 64.6% 5,681 24.4% 2,018 4,711 4,492 4,443 4,452 1526 1,437 11.3% 723 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Mix 17% 19% 17% 15% 17% 30% 31% 26% Emerging 34% 35% Markets Acute 83% 81% 83% 85% 83% Chronic 70% 69% 74% Regulated 66% 65% Markets Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 • Regulated markets contributed 83% of Q1F
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 617 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 370+ 30+ 162 187 70+ 10+ 120 22 170+ 617 50+ 10+ DMFs and 101 25 (Brazil) CEPs 14 Regulated Emerging India - Mix of Regulated Number of
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend North (In ₹ Mill i on ) Therapy Europe Japan Brazil Australia ROW Total America % of Total Revenue CVS 40 41 4 27 11 41 164 CNS 45 26 8 21 4 22 126 Anti-Infective 21 11 3 3 3 15 56 3.7% Diabetes 10 5 - 9 1 18 43 3.6% 3.3% 3.4% Dermatology 9 6 1 13
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure* Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ank
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches New Growth levers 2 ✓ Geographical expansion ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms ✓ Iron compounds ✓ Oncology & HP A
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~100KL Capacity Q4 FY27 Brownfield API Dahej Planned addition of ~160KL Capacity Q3 FY27 Phase 1 - ~350 KL (API and Backward Integra
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE SNEHA SALIAN Email: diwakar.pingle@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 Technopolis Knowledge Park, A Wing, P